1	Supplementary Information
2	This file contains Supplementary Note 1-11 and Supplementary Figures 1-9 followed by the
3	Supplementary Note-only References.
4	The Table of Contents is as follows:
5	
6	Supplementary Note 1-11:
7	
8	Supplementary Note 1A: Characterizing newly defined cis-pQTLs within European and African
9	ancestries
10	
11	Supplementary Note 1B: Further details on defining "strict variant-to-gene" (strict V2G)
12	cis-pQTLs
13	
14	Supplementary Note 1C: Further details on instrumentable proteins in each cohort
15	
16	Supplementary Note 2: Assessing sample overlap in two-sample MR for UK Biobank GWAS
17	outcomes and proteomics cohort
18	
19	Supplementary Note 3: Cohort level description of putatively causal protein-phenotype pairs in
20	European and African ancestry
21	
22	Supplementary Note 4: Proteins involved in a multitude of traits and diseases
23	
24	Supplementary Note 5A: Validating cardiovascular related putatively causal protein-phenotype
25	pairs from prior studies in European ancestries
26	
27	Supplementary Note 5B: Validating non-cardiovascular disease related putatively causal
28	protein-phenotype pairs from prior studies in European ancestries
29	
30	Supplementary Note 5C: Exploratory analyses using ARIC African proteomics cohort to
31	assess causal effects on binary cardiovascular and autoimmune-related outcomes in the Million
32	Veteran Program
33 34	Supplementary Note 5D: Additional note on uniquely instrumentable proteins in East Asian
35 35	ancestry and putatively causal protein-phenotype pairs from these proteins
36	ancesity and putatively causal protein-priendlype pairs nom these proteins
30 37	Supplementary Note 6: Discordant effects across ancestries for putatively causal protein-
38	phenotypes pairs
39	phenolypes pairs
40	Supplementary Note 7A: Druggability of instrumentable protein-coding genes at the cohort
40 41	level
41	
42 43	Supplementary Note 7B: Overlap of protein-phenotype pairs stratified by ancestry in the
43 44	druggable genome and DrugBank
45	
-1-5	

46 47 48	<b>Supplementary Note 7C:</b> Druggability of protein-phenotype pairs by integrating the druggable genome, DrugBank, and Open Targets Platform
49 50	Supplementary Note 8: Prioritization of targets for CAD and T2D
50 51 52	Supplementary Note 9: Detailed description of Kyoto University Nagahama East Asian cohort
53 54	Supplementary Note 10: Detailed description of PWCoCo and SharePro
55 56 57	Supplementary Note 11: STROBE-MR checklist
58 59 60	Supplementary Figure 1-9:
61 62	Supplementary Figure 1. Within-ancestry <i>cis</i> -pQTL effect size concordance.
63 64 65	Supplementary Figure 2. Protein-phenotype network plots for other phenotypes in European ancestry; six phenotype categories)
66 67 68	Supplementary Figure 3. Protein-phenotype pairs with discordant direction across ancestries.
69 70 71	Supplementary Figure 4. The overlap between instrumentable protein-coding genes and the druggable genome from Finan et al.
72 73 74	Supplementary Figure 5. UpSet plot showing the overlap between instrumentable proteins and the druggable genome across three ancestries.
75 76 77	Supplementary Figure 6. UpSet plot showing the overlap between instrumentable proteins and the druggable genome across 7 cohorts.
78 79 80	Supplementary Figure 7. European ancestry druggability heatmaps for 12 disease categories.
81 82 83	Supplementary Figure 8. East Asian ancestry druggability heatmaps for 11 disease categories.
84 85 86 87	Supplementary Figure 9. Prioritizing proteins for coronary artery disease and type 2 diabetes.
88 89	Supplementary Note-only References

## 90 Supplementary Note 1-11:

91

92 **Supplementary Note 1A:** Characterizing newly defined cis-pQTLs within European and African 93 ancestries

- To verify that newly defined *cis*-pQTLs were comparable, we assessed the within-ancestry concordance of *cis*-pQTL effect sizes in European (**Supplementary Figure 1a**) and in African ancestries (**Supplementary Figure 1b**). We found high concordance of effects suggesting that within each ancestry, the newly defined *cis*-pQTLs are comparable.
- 98
- 99 Methods:

We assessed the within-ancestry concordance between European ancestry proteomics cohorts
 by aligning the effect allele of *cis*-pQTLs in each cohort to the minor allele in the UKB 50k
 reference panel. Similarly, when comparing the within-ancestry concordance between African

ancestry proteomics cohorts, we first aligned effect alleles of *cis*-pQTLs in each cohort to the

104 minor allele of the corresponding variant in the African ancestry HGDP+1kGP reference panel.

105 106

## 107 **Supplementary Note 1B:** Further details on defining "strict variant-to-gene" (strict V2G)

- 108 cis-pQTLs
- 109

110 Upon defining *cis*-pQTLs in each cohort, we performed two additional steps to select genetic 111 instruments which we term strict V2G *cis*-pQTLs.

112

First, to minimize potential horizontal pleiotropic effects, we removed *cis*-variants associated with two or more protein-coding genes (**Supplementary Note Table 1**), thus retaining *cis*-pQTLs associated with a single protein-coding gene, which we term "strict" *cis*-pQTLs.

116

117 Second, we leveraged multiple sources of evidence to assign variants to genes using Open 118 Targets Genetics V2G score. As expected, upon performing strict V2G filtering within each cohort, 119 we found that strict V2G cis-pQTLs had a larger proportion of proteins with a single associated 120 cis-pQTL compared to all cis-pQTLs (Supplementary Note Table 2), and the maximum number 121 of *cis*-pQTLs associated with a single protein was either the same or lower across all cohorts in all ancestries (Supplementary Note Table 3). The number of strict V2G cis-pQTLs for each 122 123 protein is shown in **Supplementary Note Table 4**. The maximum number of strict V2G *cis*-pQTLs 124 per protein was larger in all European ancestry cohorts compared to African ancestry cohorts and 125 the Kyoto University Nagahama East Asian ancestry cohort (Supplementary Note Table 3). For 126 example, the UKB-PPP European ancestry cohort had a range of 1 up to 21 strict V2G cis-pQTLs 127 per protein while the number of strict V2G *cis*-pQTLs per protein in the Kyoto University 128 Nagahama East Asian ancestry cohort ranged from 1 to 3.

- 129
- 130

## 131 **Supplementary Note 1C:** *Further details on instrumentable proteins in each cohort*

132

133 In European ancestries, we identified 1,485 instruments for 1,102 proteins for ARIC (n = 7,213; **Supplementary Table 2**), 2,083 instruments for 1,243 proteins for deCODE (n = 35,559; **Supplementary Table 3**), 1,637 instruments for 1,194 proteins for Fenland (n = 10,708; **Supplementary Table 4**), and 2,194 instruments for 1,292 proteins for UKB-PPP (n = 34,557; **Supplementary Table 5**). In African ancestries, we identified 1,080 instruments for 877 proteins 138 for ARIC (n = 1,871; **Supplementary Table 6**), and 604 instruments for 554 proteins for UKB- 139 PPP (n = 931; **Supplementary Table 7**). Finally, in the Kyoto University Nagahama East Asian 140 ancestry cohort, 663 instruments were identified from 602 proteins (n = 1,823; **Supplementary** 141 **Table 8**).

142

143 We also assessed whether any instrumentable proteins were shared across cohorts within European and African ancestries. Here, we use proteins to refer to the protein-coding gene name 144 145 in order to avoid double counting SomaScan v4 aptamers and to enable harmonization with Olink 146 assays. Protein-coding genes were quantified based on Ensembl gene IDs. Within European 147 ancestries, 434 proteins were shared across all fours cohorts while 375 were unique to the ARIC, 148 deCODE, and Fenland cohorts measured with the SomaScan v4 platform, and 652 were unique 149 to the UKB-PPP cohort which measured proteins using Olink Explore 3072 (Extended Data Fig. 150 4a), highlighting the value of using two proteomics platforms. In African ancestries, 259 proteins 151 were jointly instrumentable by the ARIC and UKB-PPP cohorts while 591 were unique to ARIC 152 and 294 to UKB-PPP (Extended Data Fig. 4b) which emphasizes the value of having two cohorts 153 from two separate proteomics platforms. The Kvoto University Nagahama East Asian cohort (n =154 1,823) was able to instrument 581 proteins (Extended Data Fig. 4c).

#### 155 **Supplementary Note 2:** Assessing sample overlap in two-sample MR for UK Biobank GWAS 156 outcomes and proteomics cohort

157

To estimate the extent of bias in two-sample MR causal estimates for European exposures that use proteomics GWAS from the UKB-PPP and European GWAS outcomes that were generated from LIK Biobank individuals, we calculated relative bias<sup>1</sup> based on the equation:

160 from UK Biobank individuals, we calculated relative bias<sup>1</sup> based on the equation:

161

Relative bias = 
$$\phi \times \frac{1}{F}$$

162 The proportion of sample overlap,  $\phi$ , ranges between 0 (no sample overlap) and 1 (complete 163 sample overlap), while the F-statistic of the exposure is denoted by *F*. Assessments of sample 164 overlap for the European UKB-PPP and African UKB-PPP proteomics cohorts and corresponding

165 UKB outcomes are shown in **Supplementary Note Table 5**.

166

Since 51 of 179 European GWAS outcomes were based on the UK Biobank, we estimated the extent of potential bias towards the null due to sample overlap in two-sample MR causal estimates for European exposures that used proteomics GWAS from the UKB-PPP (n = 34,557). The relative bias<sup>1</sup> when assuming maximum overlap between proteomics GWAS and the 51 UKB outcome GWAS using the minimum F-statistic of 29.8 was estimated to be between 0.250% and 0.769% (**Supplementary Note Table 5**). However, we note that we utilized three additional proteomics cohorts from ARIC, deCODE, and Fenland which may consequently provide further levels of support for these protein-phenotype associations and mitigate this bias

174 levels of support for these protein-phenotype associations and mitigate this bias.

#### 175 **Supplementary Note 3:** Cohort level description of putatively causal protein-phenotype pairs in

#### 176 European and African ancestry

177

Our analysis involves two different levels of resolution when describing the results. At the ancestry level, this pertains to European, African, and East Asian ancestries. At the cohort level this involves four cohorts (ARIC, deCODE, Fenland, and UKB-PPP) for European ancestries, two cohorts (ARIC and UKB-PPP) for African ancestries, and the Kyoto University Nagahama cohort for individuals of East Asian ancestry. In the main text, we focus findings at the ancestry level to avoid complicating the results and describe the cohort level details here:

184

185 In European ancestries, we identified a total of 6,771 putatively causal protein-phenotype associations (1,764 pairs in ARIC; 1,731 in deCODE, 1,788 in Fenland, and 1,488 in UKB-PPP) 186 pertaining to 3,949 unique pairs (Supplementary Table 14 and Extended Data Fig. 5a). In 187 188 African ancestries, we identified a total of 72 associations involving 35 associations in ARIC and 189 37 associations in UKB-PPP, with 56 unique protein-phenotype associations across both cohorts 190 involving 28 proteins and 11 phenotypes (Supplementary Table 15 and Extended Data Fig. 5b). The direction of effect was consistent among all common associations between ARIC and UKB-191 192 PPP including well known proteins known to affect HDL cholesterol such as APOC1, CD36, 193 DPEP2, and ITIH4 serving as positive controls.

194

195

## 196 **Supplementary Note 4:** *Proteins involved in a multitude of traits and diseases*

197

198 When quantifying the number of associated phenotypes that each protein was associated with. 199 we found pleiotropic proteins associated with up to 49, 5, and 58 unique phenotypes in European, 200 African, and East Asian ancestries, respectively (Supplementary Note Table 6). In European 201 ancestries, 13 proteins were putatively causal for 20 or more outcomes including GCKR, GPN1, 202 BTN3A2, SORT1, RSPO3, HP, RAB21, TIMD4, MST1, APOB, EFEMP1, PCSK9, and PLCG1. 203 Since some phenotype categories had a greater number of outcomes than other categories, we 204 guantified the number of associated phenotype categories each protein was implicated in as well 205 (Supplementary Note Table 7). These targets present complex scenarios and may have effects 206 in multiple tissues or organs.

207

208 For example, in European ancestries, GCKR (implicated in 10 phenotype categories) increases 209 the risk of type 2 diabetes as previously reported<sup>2</sup> but our study shows that it also decreases the 210 risk of inflammatory bowel disease (IBD) and cholelithiasis. MST1 (9 phenotype categories) is a 211 macrophage-stimulating protein and hepatocyte growth factor-link protein highly expressed in the 212 liver, suggesting its involvement in immune-related and liver diseases. MST1 has been implicated 213 in IBD<sup>3</sup> and its pQTLs have also been found to associate with Crohn's disease, ulcerative colitis, 214 IBD, and primary sclerosing cholangitis (PSC)<sup>4</sup>, a rare liver condition associated with IBD and 215 causing severe liver scarring. We found that increased genetically predicted MST1 levels were 216 protective against IBD, including both Crohn's disease and ulcerative colitis, and PSC. However, 217 despite these protective effects, our results suggest that higher MST1 protein levels may 218 potentially lead to harmful cardiovascular events, such as increased systolic blood pressure and 219 diastolic blood pressure and a higher risk of coronary artery disease.

220

In African ancestries, APOA5, APOE, and HP had effects on the most phenotypes with both being
 associated with 5 outcomes (Supplementary Note Table 6). All proteins had effects on
 phenotypes within a single category aside from ABO and ITIH4 which were causal for outcomes
 from three and two phenotype categories, respectively (Supplementary Note Table 7).

225

226 In East Asian ancestries, ALDH2 was the most pleiotropic protein and putatively causal for 58 227 phenotypes (from 12 phenotype categories) including multiple diseases such as stroke (any 228 ischemic stroke), epilepsy, colorectal cancer, esophageal cancer, hepatic cancer, lung cancer 229 among many others. Notably, ALDH2 was not instrumented in European nor African and was 230 uniquely instrumented in East Asian ancestry. The next most pleiotropic protein in East Asian 231 ancestries was ABO associated with 14 phenotypes (4 phenotype categories) as expected due 232 to known pleiotropy at this locus. MLN, a small peptide hormone secreted by cells in the small 233 intestine which regulates gastrointestinal contractions and motility was causal for 10 phenotypes (6 phenotype categories) including cardiovascular outcomes (angina pectoris and stable angina 234 235 pectoris), gastrointestinal (chronic hepatitis B), autoimmune (rheumatoid arthritis), cancer (gastric cancer), and various biomarkers implicating its involvement in multiple biological processes and 236 237 influence in a multitude of health conditions.

238

239 To summarize, of our putatively causal findings, we identified many proteins influencing traits or 240 diseases in the same categories revealing the common mechanistic interplay between specific 241 outcomes. On the contrary, many proteins also demonstrated effects on various traits or diseases 242 that may not be directly linked to each other, underscoring the complexity of protein functions and 243 the intricate network of biological pathways involved in health and disease. For instance, a higher genetically predicted level of MST1 decreased the risk of IBD and its subtypes including both 244 245 Crohn's disease and ulcerative colitis. This protective effect is likely due to MST1's role in 246 modulating immune responses and inflammation, which are central to the pathogenesis of these

conditions. Meanwhile, increased MST1 was associated with adverse cardiovascular outcomes
 including higher risk of coronary artery disease. In the context of IBD, MST1 may enhance
 mucosal healing and modulate inflammatory pathways, contributing to its protective effects.
 Conversely, the impact of MST1 on the cardiovascular system may involve mechanisms related
 to vascular inflammation and endothelial function, leading to increased blood pressure and
 atherosclerosis, highlighting the importance of understanding context-specific regulation of these
 potential targets.

#### 254 **Supplementary Note 5A:** Validating cardiovascular related putatively causal protein-phenotype 255 pairs from prior studies in European ancestries

256

257 We validated many previously known findings for cardiovascular phenotypes in European 258 ancestries (Fig. 4a and Supplementary Figure 2a). For instance, COL6A3 (SomaScan aptamer: 259 11196-31, Olink assay: OID20292) was positively associated with coronary artery disease (CAD) 260 in all four European ancestry cohorts. This effect is concordant with our previous extensive work 261 on COL6A3<sup>5</sup>. In addition, we replicated previously reported findings of MMP12 on stroke by Sun 262 et al.<sup>6</sup> that was also further validated by Zheng et al.<sup>7</sup> who extended to stroke subtypes. Similar 263 to Zheng's study, European ancestry MMP12 pQTLs from deCODE and UKB-PPP were associated with lower risk of any ischemic stroke (deCODE: OR = 0.92, 95% CI: 0.89-0.95, P = 264 265  $1.9 \times 10^{-7}$ , PP<sub>max</sub> = 0.98; UKB-PPP: OR = 0.92, 95% CI: 0.90–0.95, P = 1.9 × 10^{-7}, PP<sub>max</sub> = 1) and large artery stroke (deCODE: OR = 0.77, 95% CI: 0.70–0.86,  $P = 6.0 \times 10^{-7}$ , PP<sub>max</sub> = 1; UKB-PPP: 266 OR = 0.79, 95% CI: 0.72–0.87,  $P = 6.0 \times 10^{-7}$ ,  $PP_{max} = 0.99$ ). 267

268

Additionally, ITIH4 was shown in a prior study using mouse lines and colocalization to act as a 269 270 novel vascular smooth muscle cell-expressed gene implicated in atherosclerotic plaques<sup>8</sup>. 271 However, genetic evidence of causality was not determined. Here, we found a positive association between ITIH4 with CAD (deCODE: OR = 1.43, 95% CI: 1.27–1.60, P = 1.5 × 10<sup>-9</sup>, PP<sub>max</sub> = 1; 272 Fenland: OR = 1.18, 95% CI: 1.12–1.25, *P* = 1.5 × 10<sup>-9</sup>, PP<sub>max</sub> = 1), pulse pressure (deCODE: β 273 274 = 1.46, 95% CI: 1.00–1.93,  $P = 5.5 \times 10^{-10}$ ,  $PP_{max} = 1$ ; Fenland:  $\beta = 0.69$ , 95% CI: 0.47–0.91, P = $5.5 \times 10^{-10}$ , PP<sub>max</sub> = 0.99), and systolic blood pressure (deCODE:  $\beta$  = 1.66, 95% CI: 0.98–2.34, 275  $P = 1.8 \times 10^{-6}$ ,  $PP_{max} = 0.97$ ; Fenland:  $\beta = 0.78$ , 95% CI: 0.46–1.11,  $P = 1.8 \times 10^{-6}$ ,  $PP_{max} = 0.94$ ), 276 277 consistent with and confirming the findings of earlier research using animal studies. 278

Interestingly, we also identified a few proteins that were protective against cardiovascular events. For example, SWAP70 was protective against coronary artery disease (ARIC: OR = 0.95, 95% CI: 0.93–0.96,  $P = 5.7 \times 10^{-11}$ , PP<sub>max</sub> = 1; deCODE: OR = 0.92, 95% CI: 0.89–0.96,  $P = 1.5 \times 10^{-9}$ , PP<sub>max</sub> = 0.94), small vessel stroke (deCODE: OR = 0.78, 95% CI: 0.68–0.89,  $P = 2.6 \times 10^{-4}$ , PP<sub>max</sub> = 0.84), and any ischemic stroke (ARIC: OR = 0.94, 95% CI: 0.92–0.97,  $P = 4.5 \times 10^{-6}$ , PP<sub>max</sub> = 0.98; deCODE: OR = 0.90, 95% CI: 0.86–0.95,  $P = 3.0 \times 10^{-5}$ , PP<sub>max</sub> = 0.92).

286 PTN was protective against peripheral artery disease in two cohorts (Fenland: OR = 0.79, 95% 287 Cl: 0.70–0.89,  $P = 7.5 \times 10^{-5}$ , PP<sub>max</sub> = 0.97, and UKB-PPP: OR = 0.49, 95% Cl: 0.37–0.65, P = 288 8.5 × 10<sup>-7</sup>, PP<sub>max</sub> = 0.89), mood swings (deCODE: OR = 0.98, 95% Cl: 0.97–0.99,  $P = 1.4 \times 10^{-5}$ , 289 PP<sub>max</sub> = 0.81; Fenland: OR = 0.97, 95% Cl: 0.96–0.99,  $P = 1.4 \times 10^{-5}$ , PP<sub>max</sub> = 0.84), and 290 anthropometric outcomes such as waist-to-hip ratio (deCODE:  $\beta = -0.04$ , 95% Cl: -0.06, -0.03, P291 = 2.3 × 10<sup>-6</sup>, PP<sub>max</sub> = 0.97; Fenland:  $\beta = -0.04$ , 95% Cl: -0.07, -0.03,  $P = 4.0 \times 10^{-6}$ , PP<sub>max</sub> = 0.95). 292

Further, DKKL1 was previously reported as putatively causal for multiple sclerosis<sup>9</sup> which we also found (ARIC: OR = 0.46, 95% CI: 0.37–0.58,  $P = 3.5 \times 10^{-11}$ , PP<sub>max</sub> = 1; Fenland: OR = 0.28, 95% CI: 0.19–0.41,  $P = 4.3 \times 10^{-11}$ , PP<sub>max</sub> = 1), but here we also identified it as protective against risk of large artery stroke (ARIC: OR = 0.59, 95% CI: 0.44–0.79,  $P = 4.2 \times 10^{-4}$ , PP<sub>max</sub> = 0.87; Fenland: OR = 0.42, 95% CI: 0.26–0.67,  $P = 3.0 \times 10^{-4}$ , PP<sub>max</sub> = 0.89) as well as metabolic/endocrine disorders such as hypothyroidism/myxoedema (ARIC: OR = 0.99, 95% CI: 0.98–0.99,  $P = 1.2 \times 10^{-5}$ , PP<sub>max</sub> = 0.95; Fenland: OR = 0.98, 95% CI: 0.97–0.99,  $P = 2.6 \times 10^{-5}$ , PP<sub>max</sub> = 0.84).

300 301

## 302 **Supplementary Note 5B:** Validating non-cardiovascular disease related putatively causal

303 protein-phenotype pairs from prior studies in European ancestries

- 304
- We also validated findings in other non-cardiovascular disease categories in European ancestries. Network plots for these associations are shown for autoimmune (**Supplementary Figure 2b**), neurological (**Supplementary Figure 2c**), psychiatric (**Supplementary Figure 2d**), metabolic/endocrine (**Supplementary Figure 2e**), and gastrointestinal phenotypes (**Supplementary Figure 2f**).
- 310
- For example, a one standard deviation increase in genetically predicted NPNT levels was associated with a decreased risk of asthma which is consistent with findings in our previous work<sup>10</sup>.
- Notably, increased levels of genetically predicted RAB21 was protective against Parkinson's disease and associated with increased cognitive performance and educational attainment consistent with findings of the involvement of RAB21 in neuronal development<sup>11</sup> (**Supplementary Figure 2c**). Further, RAB21 has been implicated in obesity in concord with our findings showing protective effects of RAB21 on visceral (VAT), abdominal subcutaneous (ASAT), and gluteofemoral (GFAT) adipose tissue volumes (**Supplementary Figure 2e**).
- 320
- INHBB has previously been implicated in serum urate levels<sup>12</sup> and in our analysis was found to be positively associated with urate and negatively associated with estimated glomerular filtration rate in all four European ancestry cohorts. In addition, we found a positive effect of genetically predicted INHBB levels on risk of type 2 diabetes in the UKB-PPP cohort (OR: 1.09, 95% CI: 1.04–1.13 per standard deviation (s.d.) increase in the protein level,  $P = 9.8 \times 10^{-5}$ ,  $PP_{max} = 1$ ) which had not previously been reported.
- 320

Lastly, STAT3 was positively associated with inflammatory bowel disease but negatively associated with multiple sclerosis which is concordant with recent findings showing opposite effects across these two diseases<sup>13</sup> and supported by an earlier randomized, placebo-controlled multicenter study showing divergent outcomes of anti-TNF therapies, which are effective for inflammatory bowel disease but worsen multiple sclerosis<sup>14</sup>.

333 334

Supplementary Note 5C: Exploratory analyses using ARIC African proteomics cohort to
 assess causal effects on binary cardiovascular and autoimmune-related outcomes in the Million
 Veteran Program

- We identified 7 putatively causal associations for binary cardiovascular outcomes which are
  shown in **Supplementary Note Table 8**. The protein PCYOX1 was implicated in all diseases.
- 341
- 343 Supplementary Note 5D: Additional note on uniquely instrumentable proteins in East Asian
   344 ancestry and putatively causal protein-phenotype pairs from these proteins
- 345
- Of the 325 unique protein-phenotype pairs identified in the Kyoto University Nagahama East
- Asian ancestry cohort, we found that 67 (20.6%) protein-phenotype associations were from 8 proteins (ALDH2, ANXA7, APOA1, DDOST, GSS, PLA2G7, PRSS2, UGT1A1) specific to East
- Asian and not instrumentable by European nor African ancestries. For instance, in European
- ancestry, ALDH2 had no genome-wide significant pQTLs in ARIC, and upon LD clumping, only
- had *trans*-pQTLs in UKB-PPP, while in both Fenland and deCODE, the strict *cis*-pQTL did not

have the highest V2G score and was filtered out given the risk of horizontal pleiotropy. Similarly,

- in African ancestries, ALDH2 had no genome-wide significant pQTLs upon LD clumping.
- 354

355 An example of one association from uniquely instrumentable proteins in East Asian ancestry is

APOA1 and cholesterol levels. APOA1 was positively associated with both HDL cholesterol and

- total cholesterol levels concordant with its function as the main protein in high density
- lipoproteins mediating efflux of cholesterol. Additionally, causal effects of UGT1A1 on total
- bilirubin has been previously identified in African ancestries<sup>15</sup> and our study supports these
- 360 findings in East Asian ancestries ( $\beta$  = -0.44, 95% CI: -0.46, -0.43, *P* = 1.00 × 10<sup>-300</sup>, PP<sub>max</sub> = 1).
- 361

#### 362 **Supplementary Note 6:** *Discordant effects across ancestries for putatively causal protein-*

#### 363 phenotypes pairs

364

365 For putatively causal associations with inconsistent MR effect estimates across ancestries, we 366 identified 12 protein-phenotype pairs involving 9 proteins and 6 phenotypes, composed of lipid 367 and anthropometric traits (Supplementary Figure 3). One pair showed discordant MR estimates 368 across all three ancestries, four were discordant between European and African ancestries, and 369 seven between European and East Asian ancestries. For instance, ABO was negatively 370 associated with total cholesterol levels in Europeans but positively associated in African and East 371 Asian ancestries. This discrepancy may require further study due to the high-impact PAV 372 instrumental variable used for ABO in African ancestries (Supplementary Table 15). Similar discordance was seen with ABO and LDL cholesterol: negative in Europeans and positive in East 373 374 Asian ancestries, likely due to ABO's pleiotropic nature. CD36 also showed discordant 375 associations: positively associated with HDL cholesterol in Europeans (deCODE, Fenland, UKB-PPP) but negatively in Africans (ARIC, UKB-PPP), and negatively associated with triglycerides in 376 377 Europeans but positively in Africans. The *cis*-pQTL proxying CD36 in African ancestries was a high-impact PAV. While increased CD36 typically decreases HDL and increases triglycerides, a 378 379 previous study showed an inverse relationship between monocyte CD36 and HDL in African 380 ancestries<sup>16</sup>, aligning with our findings. Other discordant associations included DEF6 with height 381 (negative in Europeans, positive in Africans) and CA4 (positive in Europeans, negative in 382 Africans). Between European and East Asian ancestries, discordance was found for GHR and 383 AOC1 with height, APOB with LDL and total cholesterol, and ACP1 with body mass index. Notably, 384 GHR and height associations were inconsistent within European cohorts (deCODE and UKB-385 PPP). likely due to differences in proteomics platforms. 386

- 387 We also identified discordant effects for phenotypically related outcomes that were not exact 388 matches and highlight an example using APOB. APOB plays a predominant role in the etiology of coronary artery disease as shown in recent studies<sup>17-19</sup>. Likewise, our results showed that 389 APOB was positively associated with coronary artery disease (CAD) in European ancestries with 390 391 evidence in deCODE ( $\beta$  = 0.65, 95% CI: 0.51–0.80, *P* = 3.4 × 10<sup>-18</sup>, PP<sub>max</sub> = 1), and Fenland ( $\beta$  = 0.43, 95% CI: 0.33–0.53, P = 2.9 × 10<sup>-18</sup>, PP<sub>max</sub> = 1). However, APOB in East Asian ancestries 392 393 was found to be negatively associated with myocardial infarction ( $\beta$  = -0.08, 95% CI: -0.11,-0.05, 394  $P = 1.4 \times 10^{-8}$ , PP<sub>max</sub> = 1), LDL cholesterol ( $\beta = -0.06$ , 95% CI: -0.07, -0.05,  $P = 1.3 \times 10^{-30}$ , PP<sub>max</sub> = 1), HMG CoA reductase inhibitors ( $\beta$  = -0.14, 95% CI: -0.16, -0.12, P = 3.1 × 10<sup>-44</sup>, PP<sub>max</sub> = 1), 395 396 and vasodilators used in cardiac diseases ( $\beta$  = -0.06, 95% CI: -0.08, -0.03, P = 5.0 × 10<sup>-6</sup>, PP<sub>max</sub> 397 = 0.98). When querying the instruments used for APOB in European ancestries in Open Targets 398 Genetics we found that the single *cis*-pQTL proxying APOB in deCODE, rs563290, and Fenland, 399 rs541041, were intergenic variants (Ensembl VEP impact: Modifier). In contrast, the most severe 400 consequence of the pQTL for APOB in East Asian ancestries, rs13306194, was missense 401 (Ensembl VEP impact: Moderate) and could potentially be altering epitope binding rather than 402 being a true biological signal. Nonetheless, this pQTL may still hold biological significance due to 403 being the top hit from variant-to-gene mapping, although further investigation may be required.
- 404

In summary, while inconsistent effects were found across ancestries for a few protein-phenotype associations we highlight that in three associations, ABO with total cholesterol levels, CD36 with HDL cholesterol levels, and CD36 with triglycerides, the protein level in African ancestries was a PAV of high impact so we advise caution in the interpretation of these results. Further, ABO is known to play a multi-faceted role in diseases and pQTLs at this locus have been associated with many proteins<sup>6</sup>. However, since we used variant-to-gene mapping which leverages biological evidence to select instruments, these PAVs of high impact may potentially still be functionally relevant. Notably, we found that decreased CD36 in African ancestries was associated with
 increased HDL cholesterol which was consistent with findings from a previous study<sup>16</sup>. Thus,
 further exploration may be required with larger sample sizes to elucidate whether these findings
 are biologically plausible.

#### 417 **Supplementary Note 7A:** *Druggability of instrumentable protein-coding genes at the cohort*

- 418 *level*
- 419

420 We compared instrumentable protein-coding genes against the druggable genome composed of 421 4,479 genes from Finan et al.<sup>20</sup> which classifies genes into Tier 1, 2, or 3 according to druggability. Tier 1 refers to efficacy targets of approved small molecules, biotherapeutic drugs, and clinical-422 423 phase drug candidates; Tier 2 includes proteins closely associated with drug targets or linked to drug-like compounds; Tier 3 encompasses secreted or extracellular proteins, those distantly 424 425 related to approved drug targets, and proteins from important druggable gene families not covered 426 in Tier 1 or Tier 2. All ancestries had proportionally comparable number of instrumentable protein-427 coding genes in Tier 1 and 2 (Supplementary Figure 4).

428

We found that 71, 29, and 210 proteins were shared in Tier 1, Tier 2, and Tier 3 across three ancestries, respectively (**Supplementary Figure 5**) while 26, 10, and 78 proteins were shared in Tier 1, Tier 2, and Tier 3 among all seven cohorts across three ancestries, respectively (**Supplementary Figure 6**).

- 433 434
- 435 **Supplementary Note 7B:** Overlap of protein-phenotype pairs stratified by ancestry in the
- 436 druggable genome and DrugBank
- 437
- 438 7B.1 Druggable genome

We found that 57.7%, 78.5% and 74.2% of putatively causal protein-phenotype associations in European, African, and East Asian ancestries, respectively, overlapped with the druggable genome (**Supplementary Note Table 9**).

- 442
- 443 7B.2. DrugBank

Across ancestries, a similar proportion of proteins from the putatively causal protein-phenotype associations—33.6% in European, 35.7% in African and 35.5% in East Asian ancestry—had approved or investigational drugs available based on DrugBank<sup>21</sup> (**Supplementary Note Tables 10–12**).

- 448 449
- 450 **Supplementary Note 7C:** *Druggability of protein-phenotype pairs by integrating the druggable* 451 *genome, DrugBank, and Open Targets Platform*
- 452

We provide druggability visualization for proteins implicated in various diseases (stratified by disease category) which may be potentially explored as opportunities for drug development for European (**Supplementary Figure 7**) and East Asian ancestries (**Supplementary Figure 8**). For instance, increased genetically predicted ANGPTL4 (Tier 3 target) leads to increased risk of CAD (**Supplementary Figure 7 - Cardiovascular**).

- 459 **Supplementary Note 8:** *Prioritization of targets for CAD and T2D*
- 460

461 We applied filtering steps to prioritize proteins involved in CAD (Supplementary Figure 9a) and T2D (Supplementary Figure 9b). See Supplementary Note 8 Methods below. In European 462 463 ancestries, we found directional concordance between MR estimates and hazard ratios from 464 Cox regression for incident CAD for 18 proteins, ANGPTL4, C1R, C1S, COL6A3, COMT, DDT, DUSP13, FES, FN1, IL6R, ITIH4, MST1, PCSK9, PDE5A, PLG, SCARF2, TGFB1, and TIMP2. 465 466 Two of these proteins, ITIH4 and ANGPTL4 were putatively causal for more than one phenotype in African ancestries, albeit for different outcomes, while three proteins, IL6R, 467 468 PCSK9, and PLG were putatively causal for more than one phenotype in East Asian ancestries 469 (Supplementary Figure 9a, Supplementary Note Table 13). 470 471 We also found directional concordance between MR estimates and hazard ratios from Cox regression for incident T2D for 8 proteins, ACE, ANGPTL4, INHBB, LRIG1, MINDY1, PAM, 472 PAPPA, and TFRC in European ancestries. ANGPTL4 was the only putatively causal protein from 473 474 this list present in African ancestries while in East Asian ancestries, three of these proteins, INHBB, 475 LRIG1, and TFRC were putatively causal (Supplementary Figure 9b, Supplementary Note

476 **Table 14**).477

478 We found that, in European ancestries, each standard deviation increase in ANGPTL4 levels was associated with increased odds of incident CAD (OR = 1.17, SE = 0.016,  $P = 1.89 \times 10^{-22}$ ) and 479 480 increased odds of incident T2D (OR = 1.21, SE = 0.023,  $P = 4.02 \times 10^{-17}$ ). These results are consistent with our findings from MR, where increased circulating ANGPTL4 levels were 481 482 associated with increased risk of CAD and T2D. Notably, MR estimates in African ancestries for 483 ANGPTL4 also supported this concordance in European ancestries with ANGPTL4 being 484 negatively associated with high density lipoprotein cholesterol levels and positively associated 485 with triglycerides supporting ANGPTL4 as a potential therapeutic target for intervention.

486

487 In addition, each standard deviation increase in INHBB levels was associated with a 1.19-fold 488 increased hazard of T2D (SE = 0.022,  $P = 3.63 \times 10^{-14}$ ), aligning with MR findings of increased 489 T2D risk. MR evidence in East Asian ancestries showed that higher genetically predicted INHBB 490 levels increase the risk of blood urea nitrogen and G-glutamyl transpeptidase, both linked to T2D 491 risk. However, in East Asian ancestries, reducing INHBB levels might lower HDL cholesterol and 492 raise LDL cholesterol, potentially increasing cardiovascular risk. Thus, therapeutic strategies 493 targeting INHBB must be carefully evaluated for adverse lipid profile effects. Comprehensive 494 research is needed to ensure benefits outweigh risks and to develop strategies that selectively 495 modulate INHBB without harming cardiovascular health.

496

497 We found corroborative evidence of causality between ANGPTL4 and coronary artery disease 498 and type 2 diabetes which was validated through observational association analyses on incident 499 coronary artery disease and incident type 2 diabetes risk in European ancestries. Additionally, 500 through MR we also identified similar causal roles for ANGPTL4 in African ancestries for related 501 biomarkers such as HDL cholesterol and triglycerides which were in directions congruent with our CAD and T2D findings. ANGPTL4 is an inhibitor of lipoprotein lipase (LPL) which leads to 502 503 increased triglyceride levels and prior studies have shown that the ANGPTL4 coding variant E40K 504 has been associated with lower plasma triglyceride levels<sup>22</sup> and lower risk of both CAD and T2D<sup>23</sup>. 505 While no current therapies exist for ANGPTL4, a closely related protein ANGPTL3, which also 506 inhibits LPL does and is targeted by zodasiran, an RNA interference therapy. Zodasiran targets ANGPTL3 expression in the liver and demonstrated efficacy in reducing triglyceride levels in 507 patients with mixed hyperlipidemia<sup>24</sup>. Mechanistically, ANGPTL4 and ANGPTL3 act differently. 508 509 Whereas ANGPTL3 inhibitory activity on LPL is hindered through binding to heparin, ANGPTL4

is unaffected by heparin binding suggesting that ANGPTL4 may employ distinct regulatory
 mechanisms in modulating LPL activity, potentially involving alternative molecular interactions or
 structural characteristics that confer resistance to heparin inhibition. Further research into these
 mechanisms could unveil novel therapeutic strategies for managing cardiovascular diseases.

- 514
- 515

## 516 Supplementary Note 8 Methods

517

## 518 8.1. Prioritizing targets for CAD and T2D

519 For European protein-phenotype associations, we first subsetted to those with consistent MR 520 effect across all four cohorts (ARIC, deCODE, Fenland, and UKB-PPPP) then integrated Cox 521 regression effects and determined directional concordance between MR effect estimates and 522 observational association estimates. Those with discordance between the two estimates were 523 removed and the remaining proteins were retained as potential candidates. We performed this 524 procedure for both incident CAD and incident T2D. A detailed flow diagram is shown in 525 **Supplementary Figure 9**.

526

527 We highlight that when comparing the direction of MR effect estimates with observational 528 association estimates, we removed proteins with inconsistent direction and those which did not 529 have an observational association estimate. Since Cox regression was performed on the UKB-530 PPP Olink Explore 3072 proteins, MR effect estimates from SomaScan v4 proteins would not

531 have a corresponding observational association estimate meaning proteins exclusive to

532 SomaScan v4 were not considered. Therefore, only proteins from Olink or common proteins

- 533 between SomaScan and Olink were analyzed in this analysis.
- 534

8.2. Observational associations between circulating protein abundances and incident CAD and
T2D in the UK Biobank

537 We assessed whether MR effect estimates were in alignment with observational associations as 538 this can provide an additional source of evidence supporting the purported protein-phenotype 539 association. To perform observational association analysis on incident CAD and T2D, we used 540 individual level data from the UK Biobank to determine whether circulating protein abundances 541 were able to predict future risk of these diseases based on 10 years of follow-up.

542

543 CAD was defined as in our previous study<sup>5</sup>. Briefly, we used three criteria: (i) a record of ICD-10 544 codes I20-I25 (ischemic heart disease), (ii) an operation record of percutaneous transluminal 545 coronary angioplasty (PTCA) or coronary artery bypass grafting (CABG), and (iii) a death record 546 associated with ICD-10 codes I20-I25. The time to event was determined by subtracting the event 547 registration date from the enrollment date (data field: 53), focusing on events occurring within 10 548 years of enrollment. We excluded individuals with pre-existing CAD who met these criteria prior 549 to enrollment, as well as those without a recorded event date. Controls were defined as individuals 550 without a CAD record based on doctor diagnosis (data field: 6150), self-reported heart attack 551 (data field: 20002), or an ICD-10 record of I20-I25.

552

T2D was defined using ICD-10 code E-11 while controls were defined as individuals without any
 type of diabetes based on self-reports.

555

We used Cox proportional hazards models (function: coxph()) adjusting for age, sex, BMI, recruitment center, time to Olink processing, batch, and the first 10 principal components to associate 2,922 Olink 3072 Explore platform proteins from 4,750 cases with incident CAD and 32,565 controls and 3,066 cases with incident T2D and 37,453 controls. Protein levels were inverse rank normal transformed prior to analysis.

## 561 **Supplementary Note 9:** Detailed description of Kyoto University Nagahama East Asian cohort

562

## 563 9.1. Study Cohort

Whole-genome sequencing (WGS) and proteome analysis were conducted using samples from
the Nagahama Prospective Genome Cohort for Comprehensive Human Bioscience (Nagahama
Study). A subset of 2,000 individuals (1,392 women, mean age 56.7 years; 608 men, mean age
62.0 years) was selected from 8,559 participants in the first follow-up health check (2012-2016).
Ethical approval was obtained from the Kyoto University Graduate School of Medicine and the
Nagahama Municipal Review Board (No. 278). All participants provided written informed
consent.

571

## 572 9.2. Plasma Samples and Protein Quantification

- Plasma was isolated from EDTA-treated blood by centrifugation and stored at -80 °C. Protein
  levels were measured using SomaScan assay v4, targeting 4,740 unique proteins with 5,284
  SOMAmers. After quality control, 1,997 plasma samples and 4,392 SOMAmers (4,196 proteins)
  were retained. Data were normalized and used for protein quantitative trait locus (pQTL)
  analysis. Some proteins had multiple SOMAmers targeting different forms, distinguished by
  annotations in the Somald and Target columns.
- 579

## 580 9.3. Whole-Genome Sequencing

- 581 WGS was performed on 1,573 samples using Illumina platforms and 385 samples using a 582 DNBSEQ-G400 instrument, following standard protocols (GATK and DRAGEN). After quality 583 control, including kinship analysis and variant concordance checks, 1,823 samples and 584 4,642,253 variants were retained for protein association analysis.
- 585
- 586 9.4. pQTL Analysis
- 587 Genetic associations with 4,392 SOMAmers were analyzed using PLINK (v.2.00a3LM) with age, 588 sex, variant-calling pipeline, and the first five genetic principal components as covariates. The 589 genome-wide significance threshold was set at 1.08 × 10–8 after Bonferroni correction.
- 590
- 591 9.5. Linkage Disequilibrium (LD) Clumping
- 592 LD clumping was performed using PLINK, defining clumping regions as 500 kb around index 593 variants with an LD threshold of  $R^2 \ge 0.8$ . Each region was assigned a unique ID.
- 594
- 595 9.6. Conditional Analysis
- 596 Independent signals at the loci were identified through stepwise selection in GCTA-COJO with
- 597 the following parameters: --maf 0.01 --cojo-slct, --cojo-collinear 0.9 -cojo-p 5e-8
- 598
- 599
- 600

## 601 **Supplementary Note 10:** *Detailed description of PWCoCo and SharePro*

602

We performed colocalization analyses using PWCoCo and SharePro as complementary methods to safeguard against potential putative causal associations confounded by LD and ensure higher confidence in our findings. Since differences in LD structures between populations under study can introduce bias in MR analyses, the presence of a shared causal variant between the exposure and outcome can help mitigate this issue and increase the robustness of the MR findings.

608 609

## 10.1. Pairwise conditional and colocalization analysis (PWCoCo)

610

Pairwise conditional and colocalization analysis (PWCoCo) (https://github.com/jwr-git/pwcoco) 611 612 integrates methods from conditional analyses (GCTA-COJO)<sup>25</sup> and colocalization analyses (coloc)<sup>26</sup> which relaxes the simplified single causal variant assumption of coloc thereby allowing 613 the assessment of whether multiple causal variants exist and colocalize within a region. Through 614 615 conditional analyses, independent signals from both traits (here protein GWAS and outcome 616 GWAS) can be identified and colocalization can be conducted on each pair of conditionally independent signals for the two GWAS while upholding the strict single variant assumption of 617 618 coloc. PWCoCo has been shown to outperform existing methods in scenarios where the single 619 variant assumption is violated<sup>27</sup>. It also enables the identification of previously missed disease-620 causing variants through its ability to perform independent colocalization of secondary signals 621 and offers key improvements through its computational efficiency and ease-of-use. We performed 622 PWCoCo using default settings and set the maximum number of causal variants in the region, k, 623 to 5. PWCoCo, similar to coloc, reports five colocalization probabilities: H0 - no association with 624 either trait; H1 – association with trait 1, not with trait 2; H2 – association with trait 2, not with trait 1; H3 – association with trait 1 and trait 2, two independent SNPs; H4 – association with trait 1 625 626 and trait 2, one shared SNP (i.e., the probability that both traits are associated through the sharing 627 of a single causal variant). We considered the maximum H4 posterior probability (PPH4) across 628 all tested pairs of conditionally independent signals and report evidence of colocalization if the 629 maximum PPH4  $\geq$  0.8. We note that this is different from PP<sub>max</sub> used in the main text which we 630 use to denote the maximum PP between PWCoCo and SharePro colocalization methods.

631

632 10.2. Shared sparse Projection for colocalization analysis (SharePro) 633

634 for colocalization Shared sparse Projection analysis (SharePro) 635 (https://github.com/zhwm/SharePro coloc) is a novel colocalization method which extends upon the coloc framework. SharePro uses an efficient variational inference algorithm that leverages LD 636 637 modelling and integration with colocalization assessment through grouping of correlated variants 638 into effect groups to accurately estimate posterior colocalization probabilities which together overcome the aforementioned limitations. Further, SharePro has increased power for identifying 639 640 biologically plausible signals in simulation analyses, outperforming coloc and PWCoCo while maintaining low computational cost and a low false positive rate<sup>28</sup>. We used SharePro (v.5.0.0) 641 642 default settings which sets the maximum number of causal variants in the region, K, to 10.

643

644 We emphasize that for SharePro, when K is larger than the true number of causal variants, it 645 consistently provides adequate results in comparison to setting K to the true number of causal 646 variants. Namely, K = 10 should always yield results similar to, or better than K = 5 which was set 647 in PWCoCo due to the COJO step requiring a substantial increase in computational time with a 648 larger defined K, which is not the case in SharePro.

649

For the required LD input files to SharePro, we used the UKB 50k reference panel for European,
 the HGDP + 1kGP reference panel for African, and the 1kGP East Asian reference panel for East

Asian ancestries similar to what we utilized at the LD clumping stage previously described. SharePro reports the "share" column (colocalization probabilities) for all effect groups, and we reported evidence of colocalization for the protein GWAS and outcome GWAS pair if the maximum colocalization probability of any effect group was > 0.8. We also note that this is different from  $PP_{max}$  used in the main text which we use to denote the maximum PP between PWCoCo and SharePro colocalization methods.

658

#### Supplementary Note 11:

## STROBE-MR checklist of recommended items to address in reports of Mendelian randomization studies<sup>1 2</sup>

Note: Page number will be added at the proof-reading stage.

ltem No.	Section	Checklist item	Page No.	Relevant text from manuscript
1	TITLE and ABSTRACT	Indicate Mendelian randomization (MR) as the study's design in the title and/or the abstract if that is a main purpose of the study	1, 2	Specified in the title abstract
	INTRODUCTION			
2	Background	Explain the scientific background and rationale for the reported study. What is the exposure? Is a potential causal relationship between exposure and outcome plausible? Justify why MR is a helpful method to address the study question	3	Explained in paragraph 1 of the introduction section.
3	Objectives	State specific objectives clearly, including pre-specified causal hypotheses (if any). State that MR is a method that, under specific assumptions, intends to estimate causal effects	3	Explained in paragraph 1 of the introduction section.
	METHODS			
4	Study design and data sources	Present key elements of the study design early in the article. Consider including a table listing sources of data for all phases of the study. For each data source contributing to the analysis, describe the following:		Explained in the Methods section and sources of data are presented in supplementary table 1 (ST10-12).
	a)	Setting: Describe the study design and the underlying population, if possible. Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection, when available.		The study design and the underlying population are described in the Methods section. The remainder are described in the main text.
	b)	Participants: Give the eligibility criteria, and the sources and methods of selection of participants. Report the sample size, and whether any power or sample size calculations were carried out prior to the main analysis		(b)–(e) were described in the Methods section and Supplementary Note
	c)	Describe measurement, quality control and selection of genetic variants		
	d)	For each exposure, outcome, and other relevant variables, describe methods of assessment and diagnostic criteria for diseases		
	e)	Provide details of ethics committee approval and participant informed consent, if relevant		
5	Assumptions	Explicitly state the three core IV assumptions for the main analysis (relevance, independence and exclusion restriction) as well assumptions for any additional or sensitivity analysis		Explicitly stated in the introduction and in the Methods.

6	Statistical methods: main analysis		Describe statistical methods and statistics used	
		a)	Describe how quantitative variables were handled in the analyses (i.e., scale, units, model)	(a)–(e) were described in the Methods as well as the Results section.
		b)	Describe how genetic variants were handled in the analyses and, if applicable, how their weights were selected	
		c)	Describe the MR estimator (e.g. two-stage least squares, Wald ratio) and related statistics. Detail the included covariates and, in case of two-sample MR, whether the same covariate set was used for adjustment in the two samples	
		d)	Explain how missing data were addressed	
		e)	If applicable, indicate how multiple testing was addressed	
7	Assessment of assumptions		Describe any methods or prior knowledge used to assess the assumptions or justify their validity	7–9 were described in the Methods section as well as the Results section.
8	Sensitivity analyses and additional analyses		Describe any sensitivity analyses or additional analyses performed (e.g. comparison of effect estimates from different approaches, independent replication, bias analytic techniques, validation of instruments, simulations)	
9	Software and pr registration	e-		
		a)	Name statistical software and package(s), including version and settings used	
		b)	State whether the study protocol and details were pre-registered (as well as when and where)	
	RESULTS			
10	Descriptive data	a		
		a)	Report the numbers of individuals at each stage of included studies and reasons for exclusion. Consider use of a flow diagram	Described in the Methods and Supplementary Tables.
		b)	Report summary statistics for phenotypic exposure(s), outcome(s), and other relevant variables (e.g. means, SDs, proportions)	Described in the Methods and Supplementary Tables.
		c)	If the data sources include meta-analyses of previous studies, provide the assessments of heterogeneity across these studies	Discussed in the original papers. We also evaluated the heterogeneity and horizontal pleiotropy in our analyses.

		d)	For two-sample MR: i. Provide justification of the similarity of the genetic variant-exposure associations between the exposure and outcome samples ii. Provide information on the number of individuals who overlap between the exposure and outcome studies	Described in the Methods, Results, and Supplementary Note.
11	Main results			
		a)	Report the associations between genetic variant and exposure, and between genetic variant and outcome, preferably on an interpretable scale	(a)–(c) were described in the Results.
		b)	Report MR estimates of the relationship between exposure and outcome, and the measures of uncertainty from the MR analysis, on an interpretable scale, such as odds ratio or relative risk per SD difference	
		c)	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
		d)	Consider plots to visualize results (e.g. forest plot, scatterplot of associations between genetic variants and outcome versus between genetic variants and exposure)	Described in the Methods, Results, Main Figures and Supplementary Figures using forest plots.
12	Assessment of assumptions			
		a)	Report the assessment of the validity of the assumptions	Described in the Methods and Results.
		b)	Report any additional statistics (e.g., assessments of heterogeneity across genetic variants, such as <i>I</i> <sup>2</sup> , Q statistic or E-value)	Described in the Methods and Results.
13	Sensitivity analyses and additional analyses			
		a)	Report any sensitivity analyses to assess the robustness of the main results to violations of the assumptions	(a)-(d) were described in the Methods and Results.
		b)	Report results from other sensitivity analyses or additional analyses	
		c)	Report any assessment of direction of causal relationship (e.g., bidirectional MR)	
		d)	When relevant, report and compare with estimates from non-MR analyses	
		e)	Consider additional plots to visualize results (e.g., leave-one-out analyses)	We did not perform leave-one-out analyses but assessed the robustness of the analyses using two colocalization methods (PWCoCo and SharePro)

				which are described in the Methods, Results, and Supplementary Note.
	DISCUSSION			
14	Key results		Summarize key results with reference to study objectives	Described in the Discussion.
15	Limitations		Discuss limitations of the study, taking into account the validity of the IV assumptions, other sources of potential bias, and imprecision. Discuss both direction and magnitude of any potential bias and any efforts to address them	Described in the Discussion.
16	Interpretation			
		a)	Meaning: Give a cautious overall interpretation of results in the context of their limitations and in comparison with other studies	(a)–(c) were described in the Results and Discussion.
		b)	Mechanism: Discuss underlying biological mechanisms that could drive a potential causal relationship between the investigated exposure and the outcome, and whether the gene-environment equivalence assumption is reasonable. Use causal language carefully, clarifying that IV estimates may provide causal effects only under certain assumptions	
		c)	Clinical relevance: Discuss whether the results have clinical or public policy relevance, and to what extent they inform effect sizes of possible interventions	
17	Generalizability		Discuss the generalizability of the study results (a) to other populations, (b) across other exposure periods/timings, and (c) across other levels of exposure	Described in the limitations section in the Discussion.
	OTHER INFORMATION			
18	Funding		Describe sources of funding and the role of funders in the present study and, if applicable, sources of funding for the databases and original study or studies on which the present study is based	Described in the Acknowledgments.
19	Data and data sharing		Provide the data used to perform all analyses or report where and how the data can be accessed, and reference these sources in the article. Provide the statistical code needed to reproduce the results in the article, or report whether the code is publicly accessible and if so, where	Described in the Data Availability and Code availability.
20	Conflicts of Interest		All authors should declare all potential conflicts of interest	Described in the Competing Interests


This checklist is copyrighted by the Equator Network under the Creative Commons Attribution 3.0 Unported (CC BY 3.0) license.

1. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al. Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomization (STROBE-MR) Statement. JAMA. 2021;under review.

2. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomisation (STROBE-MR): Explanation and Elaboration. BMJ. 2021;375:n2233.


#### Supplementary Figure 1. Within-ancestry *cis*-pQTL effect size concordance.

*Cis*-pQTL effect size concordance for (a) European and (b) African ancestry cohorts. In European and African ancestry proteomics cohorts, the effect allele of *cis*-pQTLs in each cohort was aligned to the minor allele of the corresponding variant in their respective reference panels—UKB 50k for European and HGDP+1kGP for African ancestry—to harmonize alleles across each ancestral cohort for plotting. Red line is the diagonal while blue line is the best-fit line with standard errors shown by blue shading. Horizontal and vertical gray dashed lines show y = 0 and x = 0, respectively.



(a) European ancestry cohorts pairwise comparison

(b) African ancestry cohorts pairwise comparison




# Supplementary Figure 2. Protein-phenotype network plots for other phenotypes in European ancestry; six phenotype categories)

Significant estimates between proteins (orange circles) and traits (green rectangles). Arrow thickness indicates how often a protein measurement has a causal effect on the outcome trait. For simplicity, we only depict protein-phenotype pairs in which all European cohorts showed concordant direction of effect estimates. Red arrows indicate a positive causal estimate of the protein on the outcome while blue arrows indicate a negative causal estimate of the protein on the outcome.


- a. Cardiovascular (binary traits only)
- b. Autoimmune
- c. Neurological
- d. Psychiatric
- e. Metabolic/endocrine
- f. Gastrointestinal


We note the following:


- Eczema appears in both Autoimmune and Skin network plots
- Type 1 diabetes appears in both Autoimmune and Metabolic/endocrine network plots
- Inflammatory bowel disease, Ulcerative colitis, Crohn's disease, and Celiac disease appear in both Autoimmune and Gastrointestinal network plots




#### b. Autoimmune









#### e. Metabolic/endocrine









Supplementary Figure 3. Protein-phenotype pairs with discordant direction across ancestries. Protein-phenotype associations that have an estimated causal effect (FDR < 0.05), passed MR sensitivity analyses, and colocalized (PP.H4 > 0.8) in either PWCoCo or SharePro but had inconsistent direction of MR effect estimates across ancestries. Sample sizes for each outcome can be found in Supplementary Tables 13, 14, and 15 for European, African, and East Asian ancestries, respectively.




## Supplementary Figure 4. The overlap between instrumentable protein-coding genes and the druggable genome from Finan et al.


The number of proteins classified into each tier when normalized by the number of instrumentable protein coding genes.






from Finan et al. The height of bars in the graphs display the










Lióco 750 500 250 0 Instrumentable proteins per ancestry

East Asian African European



Supplementary Figure 6. UpSet plot showing the overlap between

500 400 300 200 100 Instrumentable proteins per cohort

imentable proteins per conort

#### Supplementary Figure 7. European ancestry druggability heatmaps for 12 disease categories.

In the following supplementary figures, we show druggability heatmaps for different disease categories in European ancestries.

Cell color displays the MR effect estimate based on Z score averaged across cohorts capped at -10 to +10 with red showing a positive Z score indicating a positive MR effect of the protein on the phenotype and blue showing a negative Z score indicating a negative MR effect of the protein on the phenotype. For simplicity, in European ancestries, we only display protein-phenotypes with consistent effect across European cohorts. The y-axis shows the three drug databases. DrugBank (yellow square): DrugBank shows whether the protein has an available drug in the database. OpenTargets (pink square): Open Targets Platform shows whether the protein has available clinical trial information. Druggability: The druggable genome (as defined by Finan et al.) is shown for Tiers 1 (dark green, representing proteins closely related to approved drug targets or which have associated drug-like compounds), Tier 3 (light purple, representing secreted or extracellular proteins, those distantly related to approved drug targets, and members of important druggable gene families not covered in Tier 1 or Tier 2), and Unclassified (gray, all other proteins not in Tiers 1 to 3). Proteins on the y-axis within each are sorted based on the number of supported databases.

In total, for Europeans, we assessed 15 different disease categories.

However, here, we only show heatmaps for 12 disease categories and we do not show the following 3 disease categories:

- Anthropometry, due to the sheer size
- Biomarker, due to the sheer size and
- Reproductive and urogenital system, since there was only a single association.

The remaining 12 disease categories are as follows:

- 1. Cardiovascular
- since Figure 7 already shows Tier 1 and Tier 2 for Cardiovascular diseases, we show Cardiovascular Tier 3 and Cardiovascular Unclassified here.
- 2. Autoimmune
- We show the entire Autoimmune heatmap here (including Tier 3 and Unclassified) while Figure 7 only shows Tier 1 and Tier 2 for Autoimmune diseases.

For the remaining diseases, we do not stratify by druggability tier and show all protein-phenotypes together in the heatmaps.

- 3. Renal
- 4. Respiratory
- 5. Metabolic/endocrine
- 6. Neurological
- 7. Psychiatric
- 8. Musculoskeletal
- 9. Gastrointestinal
- 10. Miscellaneous
- 11. Eye

12. Cancer (all cancers are grouped together for simplicity which encompasses the following) Cancer/Skin Cancer/Metabolic disease


Cancer Cancer/Respiratory

Cancer/Neurological and psychiatric

Cancer/Gastrointestinal

Cancer/Renal

#### 1. Cardiovascular Tier 3 (Left) and Cardiovascular Unclassified (Right)



### 2. Autoimmune

10 Туре

5

0

-5


-10


Yes

Yes

No

No





## Renal

<sup>10</sup> Туре

5

0

-5

-10

Renal

DrugBank

Yes

No

Yes

No

Druggability


Tier 1

⊤ier 2


Tier 3

Unclassified

OpenTargets




#### 4. Respiratory <sup>10</sup> Туре Respiratory 5 DrugBank 0 Yes No -5 OpenTargets -10 Yes Druggability Tier 1 Tier 2 Tier 3 Unclassified





#### 9. Gastrointestinal

#### 5 Туре Туре Gastrointestinal NFKB1 SULT2A1 DrugBank 0 CD28 Yes No APOH -5 OpenTargets SERPINA1 RNASE4 Yes -10 SCPEP1 No EFEMP1 Druggability MST1 Tier 1 KITLG Tier 2 PIGR Tier 3 BTN3A2 Unclassified



11. Eye





<sup>10</sup>Туре Cancer DrugBank Yes 5 No OpenTargets Yes No 0 Druggability Tier 1 -5 Tier 2 Tier 3 Unclassified

Туре

CTSS SOST

HAGH

CD200

ARSA

TYRP1

HSD17B14

ADAMTS5

CASP9

CTSH

TGM3

KLK3

**NOTCH3** 

IL1RL1 ANXA2 SERPINB5 RNASET2 CPXM1 **BPIFB1** SPINK2 DKK2 CNTN2 ENTPD6 BTN3A2 IVD KRT5 CPNE1 CASP10 TCL1A IRF3 FAIM PKDCC KDELC2 CARD9 MYZAP

USP28 CHMP1A

Atalistant Presenting

GC

#### 10. Miscellaneous

# Supplementary Figure 8. East Asian ancestry druggability heatmaps for 11 disease categories.

In the following supplementary figures, we show druggability heatmaps for East Asian disease categories. Cell color displays the MR effect estimate based on Z score averaged across cohorts capped at -10 to +10 with red showing a positive Z score indicating a positive MR effect of the protein on the phenotype and blue showing a negative Z score indicating a negative MR effect of the protein on the phenotype. For simplicity, in European ancestries, we only display proteinphenotypes with consistent effect across European cohorts. The y-axis shows the three drug databases. DrugBank (yellow square): DrugBank shows whether the protein has an available drug in the database. OpenTargets (pink square): Open Targets Platform shows whether the protein has available clinical trial information. Druggability: The druggable genome (as defined by Finan et al.) is shown for Tiers 1 (dark green, representing efficacy targets of approved small molecules and biotherapeutic drugs), Tier 2 (dark purple, representing proteins closely related to approved drug targets or which have associated drug-like compounds), Tier 3 (light purple, representing secreted or extracellular proteins, those distantly related to approved drug targets, and members of important druggable gene families not covered in Tier 1 or Tier 2), and Unclassified (gray, all other proteins not in Tiers 1 to 3). Proteins on the y-axis within each are sorted based on the number of supported databases.

In total, for East Asians, we assessed 14 different disease categories.

However, here, we only show heatmaps for 11 disease categories and we do not show the following 3 disease categories:

- Renal, since there was only a single association.
- Eye, since there was only a single association.
- Autoimmune, since the heatmap for all proteins is already shown in Figure 8.


For the remaining diseases, we do not stratify by druggability tier and show all protein-phenotypes together in the heatmaps. All diseases are shown separately except for Neurological and Psychiatric which we group together in one heatmap for simplicity. The remaining 11 disease categories are as follows:

- 1. Cardiovascular
- We show the entire Cardiovascular heatmap here (including Tier 3 and Unclassified) while Figure 8 only shows Tier 1 and Tier 2 for Cardiovascular diseases.
- 2. Respiratory
- 3. Metabolic/endocrine
- 4. Neurological+Psychiatric (shown together for simplicity)
- 5. Gastrointestinal
- 6. Miscellaneous
- 7. Cancer
- 8. Haematology
- 9. Anthropometry
- 10. Biomarker


#### 1. Cardiovascular

#### 10 Туре Туре Туре Туре Cardiovascular APOB 5 2 Respiratory DrugBank ALDH2 ALDH2 0 0 Yes DrugBank IL6R No -2 Yes PCSK9 PLG -5 OpenTargets No ADH1B -4 Yes -10 PDCD1LG2 No -6 OpenTargets Yes Druggability SFTPD SNCA -8 Tier 1 No IGFBP3 Tier 2 MANBA CCDC80 Tier 3 Druggability 0,000,140,000 0,000,140,000 0,000,140,000 0,000,140,000 0,000,140,000,100 CITORIC OBSTRUCTIVE DUILING TRANS CIEBERSE Unclassified GAS6 Tier 1 Asthma Tier 3 HP MLN HGFAC SMOC2 OBP2B ABO SWAP70 **Droger Anderson Droger Ander** Sterns acting on the colling and the sense of the colling and the colling and the sense of the colling and the sense of sense of the se Ce Colline Collection Ale Branch and Ale Br Stope GJ is the stope LRIG1 Celture destates URSCHE AUGUERAUUS Here Contraction of the second S SIGIE HOOD RIGHT ALL Spiint Of Hotels Aitial fibrillation Children estates a states a

#### 3. Metabolic/endocrine




### 5. Gastrointestinal




# 4. Neurological and Psychiatric (shown together for simplicity)


2. Respiratory




### 6. Miscellaneous




7. Cancer



8. Haematology




#### 10. Biomarker



# Supplementary Figure 9. Prioritizing proteins for coronary artery disease and type 2 diabetes.

Flow diagram showing filtering steps for MR estimates and Cox regression observational estimates to identify potential targets for (a) coronary artery disease and (b) type 2 diabetes. CAD = coronary artery disease; OR = odds ratio; T2D: Type 2 diabetes.



#### 664 Supplementary Note-only References

- 1. Burgess, S., Davies, N. M. & Thompson, S. G. Bias due to participant overlap in two-sample
- 666 Mendelian randomization. *Genetic Epidemiology* **40**, 597–608 (2016).
- 667 2. Yuan, S. *et al.* Plasma proteins and onset of type 2 diabetes and diabetic complications:
- 668 Proteome-wide Mendelian randomization and colocalization analyses. *Cell Reports Medicine*
- **6**69 **4**, 101174 (2023).
- 670 3. High-Throughput Characterization of Blood Serum Proteomics of IBD Patients with Respect
- to Aging and Genetic Factors | PLOS Genetics.
- 672 https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1006565.
- 4. Identification of Common and Rare Genetic Variation Associated With Plasma Protein Levels
- 674 Using Whole-Exome Sequencing and Mass Spectrometry | Circulation: Genomic and
- 675 Precision Medicine. https://www.ahajournals.org/doi/10.1161/CIRCGEN.118.002170.
- 5. Yoshiji, S. *et al.* COL6A3-derived endotrophin mediates the effect of obesity on coronary
- artery disease: an integrative proteogenomics analysis. 2023.04.19.23288706 Preprint at
- 678 https://doi.org/10.1101/2023.04.19.23288706 (2023).
- 679 6. Sun, B. B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73–79 (2018).
- 680 7. Zheng, J. et al. Phenome-wide Mendelian randomization mapping the influence of the
- plasma proteome on complex diseases. *Nat Genet* **52**, 1122–1131 (2020).
- 8. Ravindran, A. et al. Translatome profiling reveals Itih4 as a novel smooth muscle cell-specific
- gene in atherosclerosis. *Cardiovascular Research* cvae028 (2024) doi:10.1093/cvr/cvae028.
- 684 9. Koprulu, M. *et al.* Proteogenomic links to human metabolic diseases. *Nat Metab* 5, 516–528
  685 (2023).
- 10. Yoshiji, S. et al. Proteome-wide Mendelian randomization implicates nephronectin as an
- 687 actionable mediator of the effect of obesity on COVID-19 severity. *Nat Metab* **5**, 248–264
- 688 (2023).

- 689 11. Peralta Cuasolo, Y. M. *et al.* The GTPase Rab21 is required for neuronal development
  690 and migration in the cerebral cortex. *Journal of Neurochemistry* **166**, 790–808 (2023).
- Köttgen, A. *et al.* Genome-wide association analyses identify 18 new loci associated with
  serum urate concentrations. *Nat Genet* 45, 145–154 (2013).
- Lincoln, M. R. *et al.* Genetic mapping across autoimmune diseases reveals shared
  associations and mechanisms. *Nat Genet* 56, 838–845 (2024).
- The Lenercept Multiple Sclerosis Study Group and The University of British Columbia
   MS/MRI Analysis Group. TNF neutralization in MS. *Neurology* 53, 457–457 (1999).
- 697 15. Chen, G. et al. A UGT1A1 variant is associated with serum total bilirubin levels, which
- are causal for hypertension in African-ancestry individuals. *npj Genom. Med.* **6**, 1–6 (2021).
- 699 16. Common CD36 SNPs reduce protein expression and may contribute to a protective
- atherogenic profile | Human Molecular Genetics | Oxford Academic.
- 701 https://academic.oup.com/hmg/article/20/1/193/2386020.
- 17. Sniderman, A. D. *et al.* Apolipoprotein B Particles and Cardiovascular Disease: A
- 703 Narrative Review. *JAMA Cardiology* **4**, 1287–1295 (2019).
- 18. Ference, B. A. et al. Association of Triglyceride-Lowering LPL Variants and LDL-C-
- Lowering LDLR Variants With Risk of Coronary Heart Disease. *JAMA* **321**, 364–373 (2019).
- 19. Ala-Korpela, M. The culprit is the carrier, not the loads: cholesterol, triglycerides and
- apolipoprotein B in atherosclerosis and coronary heart disease. *International Journal of*
- 708 *Epidemiology* **48**, 1389–1392 (2019).
- 709 20. Finan, C. *et al.* The druggable genome and support for target identification and validation
- in drug development. *Science Translational Medicine* **9**, eaag1166 (2017).
- 711 21. Wishart, D. S. *et al.* DrugBank: a comprehensive resource for in silico drug discovery
- and exploration. *Nucleic Acids Research* **34**, D668–D672 (2006).

- Smart-Halajko, M. C. *et al.* ANGPTL4 variants E40K and T266M are associated with
  lower fasting triglyceride levels in Non-Hispanic White Americans from the Look AHEAD
  Clinical Trial. *BMC Medical Genetics* **12**, 89 (2011).
- 716 23. Gagnon, E., Bourgault, J., Gobeil, É., Thériault, S. & Arsenault, B. J. Impact of loss-of-
- function in angiopoietin-like 4 on the human phenome. *Atherosclerosis* **393**, 117558 (2024).
- 718 24. Rosenson Robert S. et al. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for
- 719 Mixed Hyperlipidemia. *New England Journal of Medicine* **0**,.
- 720 25. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics
- identifies additional variants influencing complex traits. *Nat Genet* 44, 369–375 (2012).
- 722 26. Giambartolomei, C. et al. Bayesian Test for Colocalisation between Pairs of Genetic
- Association Studies Using Summary Statistics. *PLOS Genetics* **10**, e1004383 (2014).
- 724 27. Robinson, J. W. et al. An efficient and robust tool for colocalisation: Pair-wise
- 725 Conditional and Colocalisation (PWCoCo). 2022.08.08.503158 Preprint at
- 726 https://doi.org/10.1101/2022.08.08.503158 (2022).
- 727 28. Zhang, W. et al. SharePro: an accurate and efficient genetic colocalization method
- accounting for multiple causal signals. *Bioinformatics* **40**, btae295 (2024).

729